Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as E coli vaccine 1 Dose B, E coli vaccine 2, E coli Vaccine 4 Dose C
E. coli vaccine 4 · 1 trial · 1 indication
Prespecified local reactions (redness, swelling, and pain at the injection site) following each vaccination
Prespecified systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, joint pain, and muscle pain) following each vaccination
Adverse events occurring up to 1 month after the last dose of study intervention
MAEs occurring up to 12 months after the last dose of study intervention
SAEs occurring up to 12 months after the last dose of study intervention
| Arm | Type | Description |
|---|---|---|
| E coli vaccine 1 Dose A | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli vaccine 1 Dose B | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli vaccine 2 | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli vaccine 3 | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 4 Dose A | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 4 Dose B | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 4 Dose C | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 5 Dose A | EXPERIMENTAL | - |
| E coli Vaccine 5 Dose B | EXPERIMENTAL | - |
| Placebo | EXPERIMENTAL | Placebo received on day 1 and day 180 |
| Name | Type | Description |
|---|---|---|
| E coli vaccine 1 Dose A | DRUG | Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval |
| E coli vaccine 1 Dose B | DRUG | Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval |
| E coli vaccine 2 | DRUG | Candidate E coli vaccine 2, administered according to a 0, 6-month interval |
| E coli vaccine 3 | DRUG | Candidate E coli vaccine 3, administered according to a 0, 6-month interval |
| E coli Vaccine 4 Dose A | DRUG | Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval |
| E coli Vaccine 4 Dose B | DRUG | Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval |
| E coli Vaccine 4 Dose C | DRUG | Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval |
| E coli Vaccine 5 Dose A | DRUG | Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval |
| E coli Vaccine 5 Dose B | DRUG | Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval |
| Placebo | DRUG | Placebo administered according to a 0, 6-month interval |
Ages Eligible for Study: 18 to 64 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Key Inclusion Criteria 1. Adult Participants \>= 18 through \< 64 years of age at the time of enrollment. 2. Healthy participants as determined by medical history, physical examination, an...
E. coli vaccine 4 is an investigational vaccine developed by Pfizer, Inc. (ticker PFE) that is being studied in healthy adult volunteers as a potential vaccine against E. coli. It is in Phase 1 clinical development, and the specific indication it is intended to prevent has not been disclosed.
E. coli vaccine 4 is made by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the developer of the vaccine, which is currently in Phase 1 clinical development and is being evaluated in a study in the United States.
E. coli vaccine 4 is in Phase 1 clinical development. It is an investigational vaccine that has not been approved by the FDA. One Phase 1 trial is ongoing and is listed as active but not recruiting, with no completed trials reported.
E. coli vaccine 4 is being studied in trial NCT07122986, titled A Study to Learn About a Vaccine Against E Coli in Healthy Adults. The Phase 1 trial is active but not recruiting, enrolls 200 healthy participants aged 18 years and older in the United States, and is randomized, double-blind, and controlled.